Literature DB >> 17135637

Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.

Tomás Alvaro1, Marylène Lejeune, Maria-Teresa Salvadó, Carlos Lopez, Joaquín Jaén, Ramón Bosch, Lluis E Pons.   

Abstract

PURPOSE: Recent molecular data have suggested that non-neoplastic cells are powerful modulators that may confer a selective advantage or disadvantage on the outcome of follicular lymphoma (FL) patients. PATIENTS AND METHODS: The prevalence of the principal inflammatory and immune-infiltrated cells was measured immunohistochemically in the tissue of 211 FL patients, and associations were sought with their traditional clinicobiologic characteristics.
RESULTS: Our results confirmed the presence of a large number of T lymphocytes (CD4+ and CD8+) and CD57+ cells and, at a moderate level, the presence of TIA-1+ cytotoxic cells, CD68+ macrophages, CD123+ plasmacytoid cells, and FOXP3+ regulatory T cells among the pool of non-neoplastic cells. In addition to the conventional clinical variables, univariate analysis identified a low level of infiltrated CD8+ T lymphocytes as a significantly negative prognostic factor of overall survival. The following significant differences in the abundance of cells of specific and nonspecific immunity were observed in relation to the clinicobiologic features of FL: (1) a reactive microenvironment mainly made up of T lymphocytes and macrophages was significantly associated with a favorable clinical behavior of FL patients; and (2) a reactive microenvironment infiltrated predominantly by CD57+ T cells was associated with a significantly higher frequency of adverse clinicobiologic manifestations such as "B" symptoms and bone marrow involvement.
CONCLUSION: Our results demonstrate the existence of two specific patterns in the reactive microenvironment of FL, an immunosurveillance pattern (T lymphocytes and macrophages) and an immune-escape pattern (CD57+ T cells), that were directly associated with the clinicobiologic features of these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135637     DOI: 10.1200/JCO.2006.06.4766

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  70 in total

1.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

Review 2.  The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate.

Authors:  Nicolas Rachinel; Gilles Salles
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

3.  JPEG2000 for automated quantification of immunohistochemically stained cell nuclei: a comparative study with standard JPEG format.

Authors:  Marylène Lejeune; Carlos López; Ramón Bosch; Anna Korzyńska; Maria-Teresa Salvadó; Marcial García-Rojo; Urszula Neuman; Łukasz Witkowski; Jordi Baucells; Joaquín Jaén
Journal:  Virchows Arch       Date:  2010-11-18       Impact factor: 4.064

4.  Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients.

Authors:  Mehdi Dehghani; Shokouh Sharifpour; Zahra Amirghofran; Hamid Reza Zare
Journal:  Med Oncol       Date:  2012-02-04       Impact factor: 3.064

5.  Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.

Authors:  Chun Chao; Lanfang Xu; Michael J Silverberg; Otoniel Martínez-Maza; Lie-Hong Chen; Brandon Castor; Donald I Abrams; Hongbin D Zha; Reina Haque; Jonathan Said
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

6.  Automated quantification of nuclear immunohistochemical markers with different complexity.

Authors:  Carlos López; Marylène Lejeune; María Teresa Salvadó; Patricia Escrivà; Ramón Bosch; Lluis E Pons; Tomás Alvaro; Jordi Roig; Xavier Cugat; Jordi Baucells; Joaquín Jaén
Journal:  Histochem Cell Biol       Date:  2008-01-03       Impact factor: 4.304

7.  Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.

Authors:  Daphne de Jong; Ad Koster; Anton Hagenbeek; John Raemaekers; Dennis Veldhuizen; Sabien Heisterkamp; Jan Paul de Boer; Martine van Glabbeke
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

8.  Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma.

Authors:  Marylène Lejeune; Tomás Alvaro
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

9.  Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Authors:  Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

10.  Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Authors:  Jonathan W Friedberg; Jennifer L Kelly; Donna Neuberg; Derick R Peterson; Jeffery L Kutok; Rabih Salloum; Thomas Brenn; David C Fisher; Elizabeth Ronan; Virginia Dalton; Lynn Rich; Diana Marquis; Paul Sims; Paul G Rothberg; Jane Liesveld; Richard I Fisher; Robert Coffman; Tim Mosmann; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-06-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.